LigaChem Biosciences Inc. (KOSDAQ:141080)
209,000
+6,500 (3.21%)
Jan 29, 2026, 3:30 PM KST
LigaChem Biosciences Revenue
LigaChem Biosciences had revenue of 41.41B KRW in the quarter ending September 30, 2025, with 36.13% growth. This brings the company's revenue in the last twelve months to 159.27B, up 57.05% year-over-year. In the year 2024, LigaChem Biosciences had annual revenue of 125.90B with 268.71% growth.
Revenue (ttm)
159.27B
Revenue Growth
+57.05%
P/S Ratio
47.77
Revenue / Employee
936.89M
Employees
170
Market Cap
7.61T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 125.90B | 91.75B | 268.71% |
| Dec 31, 2023 | 34.15B | 733.60M | 2.20% |
| Dec 31, 2022 | 33.41B | 1.26B | 3.90% |
| Dec 31, 2021 | 32.16B | -25.34B | -44.07% |
| Dec 31, 2019 | 57.50B | 32.26B | 127.81% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SK Biopharmaceuticals | 675.41B |
| SK bioscience | 624.03B |
| PharmaResearch | 496.03B |
| Hugel | 404.19B |
| ALTEOGEN | 202.18B |
| HLB Co., Ltd. | 80.73B |
| OliX Pharmaceuticals | 10.18B |
| D&D Pharmatech | 8.36B |